Gilde Healthcare Partners recruits new partners and opens new office in the US - Gilde Healthcare

Gilde Healthcare Partners recruits new partners and opens new office in the US

10 november 2011

Utrecht, the Netherlands | Cambridge, USA – Gilde Healthcare Partners a €450 million ($600 million) venture and growth capital group based in Utrecht, Netherlands has announced the opening of its office in Cambridge, MA. The firm’s US investment activity is managed by Geoff Pardo who recently joined Gilde as Partner. Geoff has spent the last eleven years in a mix of venture capital and operating roles at Cardinal Partners, Spray Venture Partners and most recently as CEO of Facet Solutions, a spinal implant company that was sold to Globus Medical.  
In addition, Janke Dittmer joined Gilde Healthcare, in The Netherlands, as Partner. Janke has been senior director new business development and venture general manager at Philips Healthcare’s corporate venturing unit. Prior to this he was a manager at McKinsey.

Earlier this week Gilde announced the first investment from Gilde Healthcare III in Inova Labs based in Austin, TX. Inova Labs has developed a novel, proprietary portable oxygen concentrator which allows for greater patient mobility for patients suffering from Chronic Obstructive Pulmonary Disease. The new round allows Inova to expand commercialization of its flagship product, LifeChO2ice.

About Gilde Healthcare Partners

Netherlands-based Gilde Healthcare Partners is a transatlantic venture and growth capital firm focused on private healthcare technology and service companies. It has over €450 million ($600 million) under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €15 million ($20 million) in a single portfolio company. For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

Contact details

Gilde Healthcare Partners US Inc.
245 First Street, 18th floor
Cambridge, MA 02142
U.S.A.
Tel.: +1 617 395 9080

Gilde Healthcare Partners BV
Newtonlaan 91
3508 AB Utrecht
The Netherlands
Tel.: +31 30 219 2528

Gilde Healthcare co-leads in an oversubscribed £80 million Series B financing in Purespring Therapeutics

Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) Round brings in new biotech investors, Gilde Healthcare, Sofinnova...
9 oktober 2024

Gilde Healthcare company Adcendo announces IND clearance by FDA for the phase I/II study of ADCE-D01

ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma (STS) subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate...
7 oktober 2024

GILDE HEALTHCARE COMPANY SYNEXA LIFE SCIENCES ACQUIRES ALDERLEY ANALYTICAL TO EXPAND BIOANALYSIS CAPABILITIES IN DRUG DEVELOPMENT

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical Ltd, based in Manchester, UK. The transaction marks an important milestone in Synexa’s ‘buy and build’ growth strategy, underpinning...
3 oktober 2024